Table 3.
Most distant location of the first recurrence after pelvic treatment
| Local | Regional | Distant | |
|---|---|---|---|
| n (%) | 12 (9.1) | 36 (27) | 84 (64) |
| Age, median (IQR) | 65 (56–74) | 67 (54–71) | 63 (56–68) |
| Characteristics known before pelvic treatment | |||
| Treatment period, n (%) | |||
| 1969–1987 | 0 (0) | 3 (60) | 2 (40) |
| 1988–1993 | 0 (0) | 0 (0) | 3 (100) |
| 1994–2000 | 1 (5.3) | 5 (26) | 13 (68) |
| 2001–2012 | 11 (14) | 25 (32) | 43 (54) |
| 2013–2016 | 0 (0) | 3 (12) | 23 (88) |
| Moment of treatment, n (%) | |||
| Primary treatment | 7 (7.5) | 25 (27) | 61 (66) |
| Recurrence treatment | 5 (13) | 11 (28) | 23 (59) |
| Main treatment modality, n (%) | |||
| Chemoradiotherapy | 0 (0) | 2 (13) | 14 (88) |
| Neoadjuvant chemotherapy | 0 (0) | 6 (32) | 13 (68) |
| Prophylactic PLND | 11 (13) | 24 (29) | 48 (58) |
| Therapeutic PLND | 1 (7.1) | 4 (29) | 9 (64) |
| Suspicious pelvic nodes on imaging, n (%) | |||
| None | 3 (11) | 7 (25) | 18 (64) |
| Unilateral | 1 (3) | 8 (24) | 25 (74) |
| Bilateral | 0 (0) | 2 (20) | 8 (80) |
| Characteristics known after pelvic treatment | |||
| Adjuvant radiotherapy, n (%) | |||
| No | 11 (13) | 28 (32) | 49 (56) |
| Yes | 1 (3.6) | 6 (21) | 21 (75) |
| Differentiation, n (%) | |||
| Good | 1 (5.9) | 10 (59) | 6 (35) |
| Intermediate | 4 (7.1) | 12 (21) | 40 (71) |
| Poor | 7 (13) | 12 (23) | 33 (63) |
| Pathological N stage, n (%) | |||
| pN1 | 0 (0) | 1 (50) | 1 (50) |
| pN2 | 4 (44) | 3 (33) | 2 (22) |
| pN3 | 8 (9.0) | 24 (28) | 54 (63) |
| pNx | 0 (0) | 8 (23) | 27 (77) |
| Pathology pelvic nodes, n (%) | |||
| Negative | 9 (17) | 14 (26) | 30 (57) |
| Positive | 3 (5.4) | 18 (32) | 35 (63) |
| ENE, n (%) | |||
| Absent | 6 (19) | 11 (35) | 14 (45) |
| Present | 6 (7.0) | 22 (26) | 58 (67) |
IQR = interquartile range; ENE = extranodal extension; PLND = pelvic lymph node dissection.